RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Zhang, K. H. [1 ]
Singh, H. [1 ]
Twardowski, R. [1 ]
Lu, C. [1 ]
Wan, Y. [1 ]
Null, K. [1 ]
机构：
[1] Takeda Pharmaceut USA Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI4
引用
收藏
页码：S143 / S143
页数：1
相关论文
共 50 条
  • [1] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [2] Adalimumab Concentrations Following Dose Escalation in Inflammatory Bowel Disease
    Jasurda, Jake
    McCabe, Robert
    Vaughn, Byron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S437 - S438
  • [3] OUTCOMES OF DOSE ESCALATION WITH ADALIMUMAB (ADA) IN INFLAMMATORY BOWEL DISEASE
    Dillon, A.
    Rowan, C.
    Gibson, D.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    [J]. GUT, 2013, 62
  • [4] Predictors of Vedolizumab Dose Escalation or Cessation in Inflammatory Bowel Disease Patients
    Razvi, Mohammed A.
    Chowdhury, Reezwana
    Parian, Alyssa
    Melia, Joanna
    Truta, Brindusa
    Brant, Steve
    Dudley-Brown, Sharon
    Lazarev, Mark
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S417 - S418
  • [5] THE EFFECT OF INFLIXIMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTIBODIES TO INFLIXIMAB
    Tun, Gloria S. Z.
    Marshall, Laura
    Thompson, Laura
    Campbell, Rebecca
    Hale, Melissa F.
    Chew, Thean S.
    Brooks, Alenka J.
    Robinson, Kerry
    Lobo, Alan J.
    [J]. GUT, 2019, 68 : A61 - A62
  • [6] The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab
    Tun, Gloria S. Z.
    Robinson, Kerry
    Marshall, Laura
    Wright, Alison
    Thompson, Laura
    Wild, Graeme
    Sargur, Ravishankar
    Brooks, Alenka J.
    Hale, Melissa F.
    Chew, Thean S.
    Lobo, Alan J.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 295 - 301
  • [7] Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Abraham, Bincy P.
    Ritter, Timothy
    Jain, Anjali
    Cheifetz, Adam S.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (11) : 2978 - +
  • [8] Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease
    Jasurda, Jake S.
    McCabe, Robert P.
    Vaughn, Byron P.
    [J]. THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 645 - 651
  • [9] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
    Sierra Morales, M.
    Birdi, S.
    Samaan, M. A.
    Brown-Clarke, C.
    Duncan, J.
    Stanton, A.
    Koumoutsos, I.
    Anderson, S.
    Ray, S.
    Mawdsley, J.
    Sanderson, J.
    Irving, P. M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452
  • [10] Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Yarur, Andres J.
    Graziano, Elliot
    Campbell, James P.
    Bhattacharya, Abhik
    Lee, Jennifer Y.
    Gheysens, Katherine
    Papamichael, Konstantinos
    Osterman, Mark T.
    Cheifetz, Adam S.
    Cross, Raymond K.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
12345